

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

ANNOUNCEMENT

PURSUANT TO RULES 13.51(2)(U) AND 13.51B(2) OF THE LISTING RULES

This announcement is made by IVD Medical Holding Limited (the “**Company**”) pursuant to Rules 13.51(2)(u) and 13.51B(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), in relation to Mr. Lau Siu Ki (“**Mr. Lau**”), who is an independent non-executive director of the Company and a former independent non-executive director of China Medical & Healthcare Group Limited (formerly known as COL Capital Limited) (“**COL**”), a company listed on the Main Board of the Stock Exchange (Stock Code: 383).

The Company would like to inform its shareholders and potential investors that it understands from a press release of 31 October 2019 by the Hong Kong Securities and Futures Commission (“**SFC**”) that the SFC has commenced proceedings in the Market Misconduct Tribunal (the “**Proceedings**”) against COL for allegedly failing to disclose inside information as soon as reasonably practicable, and against six individuals who were COL’s directors at the material time, including Mr. Lau, for their reckless or negligent conduct causing the alleged breach of COL. For further details, please refer to the press release of 31 October 2019 on the website of the SFC under the link below:

<https://www.sfc.hk/edistributionWeb/gateway/EN/news-and-announcements/news/doc?refNo=19PR100>

The Company has been informed by Mr. Lau that he disagrees with the SFC’s allegations against him in the Proceedings, and that he intends to contest the Proceedings vigorously. In the meantime, and until the Proceedings conclude, no findings in the Proceedings have been made in respect of him.

As the Proceedings do not involve the Company or any of its subsidiaries (collectively, the “**Group**”), the Company does not consider that the Proceedings will have any material adverse impact on the businesses and/or operations of the Group.

Save as disclosed in this announcement, the Company is not aware of any other information on the above matters which needs to be brought to the attention of shareholders of the Company and there is no other information that is required to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules.

The Company will make further announcement(s) in relation to the above matters as and when appropriate in accordance with the Listing Rules.

By Order of the Board
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 4 November 2019

As at the date of this announcement, the board of directors of the Company comprises three executive directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, three non-executive directors, namely, Mr. Chen Xingang, Mr. Yang Zhaoxu and Mr. Chan Kwok King, Kingsley and three independent non-executive directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.